Sarepta Therapeutics | SRPT - Cost Of Sales

Stock Price
18.50
Daily Change
1.47 8.63%
Monthly
-21.14%
Yearly
-83.46%
Q1 Forecast
19.71

Sarepta Therapeutics reported $151.45M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025